

Open Peer Review on Qeios

Melan-A VLP Vaccine

National Cancer Institute

Source

National Cancer Institute. Melan-A VLP Vaccine. NCI Thesaurus. Code C61495.

A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response.

Qeios ID: RFZVHH · https://doi.org/10.32388/RFZVHH